Bookmark Kaumudi Online  Bookmark this site  Editor@Kaumudi  |  Marketing  Print Advt rates  |  Calendar 2012        Go!    
 
 
January 21, Saturday 2017 1:39 AM       

       HEADLINES: Milk price may be hiked by Rs 2                                              Shivpal finds place in Akhilesh Yadav's first list                                              Stalin, Kanimozhi among DMK leaders held; protesters stay put                                              Air India removes 57 over-weight crew members from flying duty                                              Hizbul Mujahideen warns people against participating in R-Day                                              New legislation to tighten H1B visas to foreign techies                                              Pak asks India, WB to inform it of all future hydel projects                                              Saina, Jayaram reach quarterfinals in Malaysia Masters                                              Probably one of my best innings, says Yuvraj Singh                                              Kaumudi Facebook
       SCI&TECH Next Article: Water exists deeper in Earth than thought: study  
       New potent vaccine may spell end for HIV
 
         Posted on :16:07:12 Nov 28, 2016
   
A A
       Last edited on:16:07:12 Nov 28, 2016
         Tags: New potent vaccine, HIV
 
WASHINGTON: The largest and most advanced HIV vaccine trial has been launched in South Africa to test the safety of a new experimental regimen that could prove to be the final nail in the coffin for the deadly virus.
 
The study, called HVTN 702, involves a new version of the only HIV vaccine candidate ever shown to provide some protection against the virus.
 
It aims to enroll 5,400 men and women, making it the where more than 1,000 people become infected with HIV every day.
 
"If deployed alongside our current armory of proven HIV prevention tools, a safe and effective vaccine could be the final nail in the coffin for HIV," said Anthony S Fauci, director of the US National Institute of Allergy and Infectious Diseases (NIAID).
 
"Even a moderately effective vaccine would significantly decrease the burden of HIV disease over time in countries and populations with high rates of HIV infection, such as South Africa," said Fauci.
 
The HIV Vaccine Trials Network (HVTN) is conducting the trial at 15 sites across South Africa. Results are expected in late 2020.
 
The experimental vaccine regimen being tested in the trial is based on the one investigated in the earlier RV144 clinical trial in Thailand led by the US Military HIV Research Programme and the Thai Ministry of Health.
 
The Thai trial delivered landmark results in 2009 when it found for the first time that a vaccine could prevent HIV infection, albeit modestly.
 
The new regimen aims to provide greater and more sustained protection than the RV144 regimen and has been adapted to the HIV subtype that predominates in southern Africa, a region that includes the country of South Africa.
 
"The people of South Africa are making history by conducting and participating in the first HIV vaccine efficacy study to build on the results of the Thai trial," said Glenda Gray, CEO of the South African Medical Research Council.
 
"HIV has taken a devastating toll in South Africa, but now we begin a scientific exploration that could hold great promise for our country," Gray said, who is also a professor at the University of the Witwatersrand.
 
"If an HIV vaccine were found to work in South Africa, it may dramatically alter the course of the pandemic," she said. The experimental vaccine regimen tested in the Thai trial was found to be 31.2 per cent effective at preventing HIV infection over the 3.5-year follow-up after vaccination.
 
In the HVTN 702 study, the design, schedule and components of the RV144 vaccine regimen have been modified in an attempt to increase the magnitude and duration of vaccine-elicited protective immune responses.
 
HVTN 702 begins just months after interim results were reported for HVTN 100, its predecessor clinical trial, which found that the new vaccine regimen was safe for the 252 study participants and induced comparable immune responses to those reported in RV144. 
A A
       SCI&TECH
Next Article: Water exists deeper in Earth than thought: study
 
 
SCI&TECH HEADLINES
Moon may have formed from collision of tiny 'moonlets'  
China to set up world's highest altitude telescopes in Tibet  
NASA to launch two robotic probes to study early solar system  
After Mars, ISRO eyes Venus and Jupiter  
New, rare galaxy spotted over 359 mln light-years away  
Coconut sized tumor removed from Iraqi woman's head  
Bacteria-powered battery built on single sheet of paper  
'Human-made objects on Earth amount to 30 trillion tonnes'  
Element 117 officially named 'Tennessine'  
Predatory bacteria may wipe out 'superbugs': study  
New potent vaccine may spell end for HIV  
Water exists deeper in Earth than thought: study  
Docs reconstruct tongue with flesh from thigh  
Why wounds take longer to heal with age decoded  
WhatsApp launches video calling to take on Google Duo, Skype  
Molecules on phone can unveil your lifestyle: study  
Chandrayaan-2 mission: ISRO conducts tests for Moon landing  
In rare surgery, 7kg tumour removed from woman's kidney  
NASA satellites break Guinness World Record  
Curiosity rover discovers rare 'Egg Rock' on Mars  
Male birth control shots may lower pregnancy odds: study  
Mysterious 'Higgs Bison' species identified  
Note 7 debacle may hit Samsung's India rev by Rs 6,500 cr: CMR  
America will take the giant leap to Mars by 2030s: Obama  
Global dust storm may hit Mars soon: NASA  
 
Azharuddin's nomination for HCA president's post was rejected. Do you agree to this?
Yes
 
No
 
Don't know
 
 
 
Home Kerala India World Business Sports Sci&Tech Education Automobile CityNews Movies Environment Letters 
© Copyright keralakaumudi Online 2011  |  Reproduction in whole or in part without written permission is prohibited.
Head Office Address: Kaumudi Buildings, Pettah P.O, Trivandrum - 695024, India.
Online queries talk to Deepu Sasidharan, + 91 98472 38959 or Email deepu[at]kaumudi.com
Customer Service -Advertisement Disclaimer Statement   |  Copyright Policy